Attovia Therapeutics (NASDAQ:ATTO) Major Shareholder Goldman Sachs Group Inc Sells 105,807 Shares of Stock

Posted by Tristan Rich on Aug 14th, 2026

Attovia Therapeutics, Inc. (NASDAQ:ATTO – Get Free Report) major shareholder Goldman Sachs Group Inc sold 105,807 shares of the business’s stock in a transaction that occurred on Wednesday, August 5th. The stock was sold at an average price of $21.28, for a total transaction of $2,251,572.96. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Goldman Sachs Group Inc also recently made the following trade(s):

On Thursday, August 6th, Goldman Sachs Group Inc bought 500,000 shares of Attovia Therapeutics stock. The stock was acquired at an average cost of $17.00 per share, for a total transaction of $8,500,000.00.
On Wednesday, August 5th, Goldman Sachs Group Inc bought 85,000 shares of Attovia Therapeutics stock. The shares were acquired at an average price of $21.00 per share, for a total transaction of $1,785,000.00.

Attovia Therapeutics Stock Up 6.2%

Attovia Therapeutics stock traded up $1.12 during trading on Thursday, reaching $19.18. 406,507 shares of the company’s stock were exchanged, compared to its average volume of 1,169,091. Attovia Therapeutics, Inc. has a 52-week low of $16.15 and a 52-week high of $22.79.

Institutional Investors Weigh In On Attovia Therapeutics

A hedge fund recently raised its position in Attovia Therapeutics stock. BlackRock Inc. lifted its stake in shares of Attovia Therapeutics, Inc. (NASDAQ:ATTO – Free Report) by 23.4% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 164,358 shares of the company’s stock after buying an additional 31,189 shares during the quarter. BlackRock Inc.’s holdings in Attovia Therapeutics were worth $317,000 as of its most recent filing with the SEC.

About Attovia Therapeutics

(Get Free Report)

Attovia Therapeutics, Inc (NASDAQ: ATTO) is a clinical-stage biopharmaceutical company developing antibody-based medicines for inflammatory and immune-mediated diseases. The company’s research is focused on creating differentiated biologic therapies intended to address significant unmet medical needs.

Attovia uses proprietary antibody-engineering technologies to discover and develop therapeutic candidates, including multispecific antibodies designed to modulate disease-related biological pathways.